Tirzepatide & Semaglutide FAQ
Medical weight loss using medications like Tirzepatide (brand name: Mounjaro) and Semaglutide (brand names: Ozempic, Wegovy, Rybelsus) is becoming increasingly popular for patients struggling with obesity. These medications work by mimicking hormones involved in regulating appetite and blood sugar levels, and are primarily used in managing type 2 diabetes but have shown significant weight loss benefits.
Frequently Asked Questions
- Tirzepatide is a dual GLP-1 (glucagon-like peptide-1) and GIP (glucose-dependent insulinotropic polypeptide) receptor agonist. It mimics these two hormones, which are involved in blood sugar regulation and appetite control. It helps reduce appetite, leading to weight loss, while improving insulin sensitivity.
- Semaglutide is a GLP-1 receptor agonist. It enhances insulin release and reduces glucagon secretion, slowing gastric emptying, which helps control blood sugar levels and decreases appetite, leading to weight loss.
- Tirzepatide is a dual agonist (GLP-1 and GIP), meaning it targets two hormone pathways, whereas Semaglutide targets only the GLP-1 pathway.
- Tirzepatide has shown in clinical trials to lead to slightly more significant weight loss compared to Semaglutide.
- Both medications are injectable, but Semaglutide also comes in an oral form (Rybelsus), while Tirzepatide is only available as an injection.
- On average, patients using Tirzepatide can lose around 15-22% of their body weight over the course of treatment.
- With Semaglutide (Wegovy), patients typically lose about 10-15% of their body weight.
- Results may vary depending on factors like starting weight, diet, exercise, and adherence to the medication regimen.
- Candidates for Semaglutide (Wegovy) or Tirzepatide include those with a BMI of 30 or higher or those with a BMI of 27 or higher with a weight-related health condition (e.g., hypertension, type 2 diabetes, or dyslipidemia).
- It is recommended for individuals who have tried lifestyle interventions (diet and exercise) without success.
- Both Tirzepatide and Semaglutide injections are self-administered using a pen device.
- Tirzepatide is usually injected once a week, starting with a low dose and gradually increasing.
- Semaglutide is also injected once a week, with a similar dosing schedule to gradually increase the dose to minimize side effects.
Common side effects for both medications include:
- Nausea
- Vomiting
- Diarrhea
- Constipation
- Indigestion
- Decreased appetite
Less common but more serious side effects can include pancreatitis, gallbladder issues, and hypoglycemia, especially if combined with other diabetes medications.
The medications are typically used long-term, as stopping them may lead to weight regain. The decision to continue or stop the treatment is made between you and your healthcare provider based on your weight loss progress and overall health goals.
Coverage for these medications varies depending on your insurance plan. Semaglutide for weight loss (Wegovy) may be covered by some plans for weight management, but Tirzepatide is primarily approved for type 2 diabetes (as Mounjaro) and may not be covered for weight loss unless the patient has diabetes.
- For the best results, these medications should be used in conjunction with a healthy diet and exercise program.
- Many patients find that these medications help them adhere to a lower-calorie diet since their appetite and cravings are reduced.
- For both medications, if you miss a dose and it’s been less than 4-5 days, take it as soon as you remember. If more than that has passed, skip the dose and take the next dose at the regular time.
- Do not double the dose to make up for a missed injection.
These medications offer a promising option for individuals struggling with obesity, but they are part of a comprehensive approach, including medical supervision, diet, and physical activity.
